RT Journal Article
SR Electronic
T1 Resurgence of malaria in Uganda despite sustained indoor residual spraying and repeated long lasting insecticidal net distributions
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.18.22271193
DO 10.1101/2022.02.18.22271193
A1 Epstein, Adrienne
A1 Maiteki-Ssebuguzi, Catherine
A1 Namuganga, Jane F.
A1 Nankabirwa, Joaniter I.
A1 Gonahasa, Samuel
A1 Opigo, Jimmy
A1 Staedke, Sarah G.
A1 Rutazaana, Damian
A1 Arinaitwe, Emmanuel
A1 Kamya, Moses R.
A1 Bhatt, Samir
A1 Rodríguez-Barraquer, Isabel
A1 Greenhouse, Bryan
A1 Donnelly, Martin J.
A1 Dorsey, Grant
YR 2022
UL http://medrxiv.org/content/early/2022/02/21/2022.02.18.22271193.abstract
AB Five years of sustained indoor residual spraying (IRS) of insecticide from 2014 to 2019, first using a carbamate followed by an organophosphate, was associated with a marked reduction in the burden of malaria in five districts of Uganda. We assessed malaria burden over an additional 21 months, corresponding to a change in IRS formulations using clothianidin with and without deltamethrin and the start of the COVID-19 pandemic. We document an unprecedented resurgence in malaria burden: in years 4-5 of sustained IRS cases were 84% lower than the pre-IRS period, in year 6 this increased to a 43% reduction, and in the first 9 months of year 7, cases were 39% higher than pre-IRS levels. The timing of this resurgence corresponded to a change of active ingredient to clothianidin, a new IRS active ingredient. Further research is needed to determine mechanisms leading to this resurgence.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Institutes of Health as part of the International Centers of Excellence in Malaria Research (ICMER) program (U19AI089674). Funding for this work was also supported by the National Institute of Allergy and Infectious Diseases (F31AI150029).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of University of California, San Francisco waived ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at https://github.com/aeepstein/resurgence-irs-uganda https://github.com/aeepstein/resurgence-irs-uganda